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Nephrology unit at Inkosi Albert Luthuli Central hospital (IALCH) caters for all 
nephrology patients in the public sector in KwaZulu Natal province. This means there is 
always a list of patients waiting for bed availability in order to be transferred across to 
the unit. Most of these patients have been inpatients at other hospitals before transfer to 
the unit and some have had urinary catheters inserted at the referring hospitals, which 
increases their risk of urinary tract infections. All patients that are seen in the unit have 
urine dipsticks and urine microscopy culture and sensitivity done as part of the 
nephrology work up. Urinary tract infections (UTI) have become a challenge because 
most invasive procedures like renal biopsies are deferred in these patients until the 
infections have been cleared, which increases hospital stay for patients in the unit and 
longer waiting period for patients waiting beds. UTI can also worsen the renal function 
leading to early requirement for renal replacement therapy thereby increasing mortality 
and morbidity. 
Early diagnosis and treatment of UTI is key on preventing complications but  increasing 
resistance of the micro-organism causing UTI to the commonly used antibiotics, 
emergence of extended beta lactam (ESBL) resistance and multiple drug resistance 
(MDR) strains is a major challenge. It is therefore vital for health care facilities to be 
aware of the resistant strain and microbial sensitivity in their facility and communities 










LITERATURE REVIEW  
UTI is among the most common causes of sepsis presenting in hospital. Forty to 50% of 
adult women have a history of at least one UTI. UTI is defined as the infection of the 
urinary system (see diagram below) which includes urethra, bladder (cystitis), ureter 




FIGURE 1 OF CHAPTER 
 
Diagram of the urinary system 
Diagram from anatomyorgan.com 
 
UTI can be symptomatic or asymptomatic (asymptomatic bacteriuria).Most micro-
organisms colonize the colon, perianal region and periurethral and introitus region in 
females 
[2].
 The frequency and severity of UTI is determined by local uroepithelial 
defense system and pathogenic factors of the micro-organisms. The common route of 
spread is ascension and the rate depends on effectiveness of the commensal flora in 
preventing colonization, local trauma such as in sexual activity and urethral massage, 
abnormalities of the urinary tract, diagnostic procedures, high vaginal pH and micro-
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organism virulence factors.The virulence factors which ensure micro-organism survival 
include fimbriae, motility, glycocalyx-mediated adherence, urease production, 




The risk of UTI is higher in elderly, pregnant women, immunocompromised, diabetic, 
post renal transplant, spinal injuries, patients admitted in the past three months, patients 
with urinary catheters and patients with urologic abnormalities 
[3-30].
 Nephrology 
patients have most of these risk factors. 
 
KwaZulu Natal province has the highest burden of HIV disease in the country
[1]
.HIV 
infected patients have higher risk of acquiring kidney disease (acute or chronic) due to 
the effects HIV virus on the renal system, immune mediated mechanisms, risk of 
infections and side effects of antiretroviral therapy (ART). 
HIV infected patients have been shown to have increased risk of UTI 
[3-6] 
, however this 
risk seem to be inversely proportional to the lymphocytes count or immune function of 
the patient 
[7-8]
. There has not been a difference in the prevalence of bacterial growth 




HIV positive patients on co-trimoxazole as a prophylaxis against  pneumocystis carinni 
do  not  have reduced incidence of UTI as  most studies have shown  that most 
uropathogen are resistant to co-trimoxazole
[12]
. 
The increased risk of urinary tract infections in pregnancy is due to hormonal and 
mechanical changes on the urinary tract during pregnancy. Pregnant women with HIV 
and urinary tract infection had a higher rate of pre-labour rupture of membranes than 
HIV negative women with urinary tract infections
[13-16]
resulting in poor maternal and 
foetal outcomes. 
 
Diabetes mellitus is a major cause of renal disease and patients with diabetes have high 
incidence of UTI
 [17-22]
. This incidence is even higher in female patients with diabetes 
mellitus
 [23, 24]
. This risk is explained by reduced T- cell mediated immune response, 
impaired bladder emptying
 [19]
 and defects in urinary cytokines secretion
 [25] 
in patients 
with diabetes mellitus. These patients do not only have high risk of acquiring UTI but 
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Patients with SLE are often seen in nephrology with Lupus nephritis. Patients with SLE 
have higher incidence of bacterial and mycotic infection compared to patients with 
Rheumatoid arthritis and Nephrotic syndrome
 [26-28]
 with even higher incidence of UTI 
[29]
. This is due to low antibody response, defective phagocytosis, decreased leucocytes 
chemotaxis, decreased lymphocyte toxic serum factors, selective defect on cellular 




UTI is the most common complication after renal transplant
 [30]
 with ABU being the 
most common manifestation
 [31]
. UTI is associated with impairment in allograft function 
[30]
. 
 E. coli is the most common cause of UTI in community acquired, hospital acquired, 
pregnant, HIV positive and negative, Diabetic, SLE and post renal transplant cohorts of 
patients
 [3-21, 29, 30, 32]
.  
E. coli is the predominant isolate in UTI in South Africa
 [33]
, continent of Africa 
[34-39]
 
and the rest of the world
 [16, 40-41]
.  Enterobacteriaceae, Klebsiella, but Pseudomonas 




Treating urinary tract infections has become a challenge due to increasing resistance to 
antibiotics
 [32, 42-45]
. There is consensus among different studies about increasing 
resistance of UTI to the commonly used antibiotics. There is also increasing rates of 
multi drug resistance
 [46, 47]
 and ESBL positive organisms
 [48, 49, 50]
. The recent data from 
Lancet laboratories in KZN region for a period 1 August 2017 to 13 July 2018 shows 
20% ESBL positive E.coli and 40% ESBL positive K. pneumonia. 
The increasing resistance has been mainly noted against Ciprofloxacin, Co-trimoxazole 
and Amoxicillin/clavulanate 
[34, 36,50-53]
. Nitrofurantoin sensitivity remains high with low 
resistance of 0% resistance in a study done in Germany
 [50]
. 
In a Study at 3 Military Hospital in Bloemfontein, South Africa,  E. coli was the most 
cultured organism but it was resistant to  mostly used antibiotics hence stressing the 
need to constantly revise empiric use of antibiotics
[32]
 
In an anti-microbial susceptibility study on Escherichia coli done in South African 
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public and private sector from 2007 to 2011 there was statistically significant changes in 
antimicrobial susceptibility noted for many antibiotics. There was a small increase in 
Ampicillin susceptibility but resistance to it was too high to allow its use as empiric 
therapy and there was a significant decline in Amikacin susceptibility but overall 
susceptibility remained above 95%. This means that for now, Amikacin can be used to 
treat pyelonephritis. Amikacin toxicity and the requirement for parenteral 
administration are drawbacks to its use. There was consistent and progressive decline in 
susceptibility to Cephalosporins and Fluoroquinolones, on both a national and local 
level. Susceptibility to Fluoroquinolones was between 70-86% at different laboratories 
in 2011, making it a major concern as these are first-line drugs that are recommended 
internationally and in the locally used Essential Drug List, and are widely used in public 
and private sectors 
[54]
. 
The antibiotics with the highest activities in 2011 were: broad-spectrum cephalosporins, 
Imipenem, Ciprofloxacin, Amikacin, and Fosfomycin, followed by Cefoxitin, 
Cephalothin, Amoxicillin-clavulanic acid, Gentamicin, Tobramycin, Nalidixic acid, Co-




Susceptibility to nitrofurantoin was above 90% and the advantage to its use was the 
limited impact on the normal gut flora 
[52, 54]
. Five years later there has been a 
significant decline in activity of the antibiotics which had high sensitivity in 2011 as 




Table provided by Dr Abdool Peer from Lancet laboratories. 
STATISTICS FROM KZN REGION ONLY: 1 AUGUST 2017 TO 13 JULY 2018: 
UNPUBLISHED DATA. 
 E. coli (% susceptible) K. pneumonia (% 
susceptible) 
Amikacin 99 95 
Ampicillin 23 4 
Augmentin 77 58 
Co-trimoxazole 43 49 
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Fosfomycin 96 90 
Ciprofloxacin 64 64 
Nitrofurantoin 98 83 
 
Prevention of UTI remains vital in reducing mortality and morbidity especially in the 
vulnerable groups. This includes improving patient’s immune status and controlling 
underlying medical condition, reducing routine catheterisation unless absolutely 
indicated, reducing duration of catheterization and intermittent catheterization which  
has been shown to reduce UTIs 
[55, 56]
. Antibiotic cycling has been used to prevent 
recurring UTIs in patients with neurogenic bladder 
[56]
. Vaginal oestrogens restore the 
vaginal lactobacilli flora, reducing colonization with Enterocteriaceae in 
postmenopausal women 
[57]
. Cranberry products have also been shown to reduce the 
























RATIONALE FOR CONDUCTING THIS STUDY 
1. The risk of acquiring UTI is high in nephrology and HIV infected patients. This risk 
should be even higher in HIV infected nephrology patients but there is limited 
literature on the incidence and antimicrobial sensitivity in nephrology patients 
specifically. This study was done to fill that gap in the literature.  
2. With the rising incidence of ESBL and MDR strains on UTI, it was important for us 
to be aware of the extent of microbial resistance and the antibiotics we use in our 


























RESEARCH QUESTION  
What is the incidence and antimicrobial susceptibility of urinary tract infection in HIV 
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CHAPTER 2  
 
2.1 THE INCIDENCE AND ANTI-MICROBIAL SENSITIVITY OF 
URINARY TRACT INFECTIONS IN HIV POSITIVE AND NEGATIVE 
NEPHROLOGY PATIENTS AT INKOSI ALBERT LUTHULI 
CENTRAL HOSPITAL IN KWAZULU NATAL PROVINCE, SOUTH 
AFRICA. 
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E. coli                     Escherichia coli 
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UTI                         Urinary tract infection 
K. pneumonia        Klebsiella pneumonia 
KZN KwaZulu Natal province 
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Background: Urinary tract infection is among the most common causes of sepsis 
presenting in hospitals.  The aim was to collect data to enable empirical treatment of 
urinary tract infections in HIV negative and positive nephrology patients while waiting 
for urine culture results in order to reduce hospital stay.  
Objectives: To assess incidence and antimicrobial susceptibility of urinary tract 
infections in HIV negative and positive patients. 
Methods: A retrospective chart review of nephrology patients admitted from 
January to December 2014 in Nephrology ward and the first consecutive 200 
outpatients seen in Nephrology clinic in 2014 at Inkosi Albert Luthuli Central Hospital 
was conducted. Information was gathered with the use of a data collection sheet and 
urinary tract infection was based on urine culture results. . All data was analysed using 
Statistical Package for Social Sciences version 23. Percentages of basic characteristics 
were calculated between groups, Logistic regression analysis was used to identify 
factors associated with positive urine culture.  
Results: There were 654 patients in the study, 514 (79%) were HIV negative and 139 
(21%) were HIV positive. The incidence of UTI in nephrology patients was 9%, 10.1% 
in inpatients and 6.5% in outpatients. 22% were HIV positive (p value 0.883, 95% CI 
0.550-2.003). 19% had Diabetes mellitus, 15% had Systemic Lupus Erythematosus and 
5% were post renal transplant patients. Escherichia coli and Klebsiella pneumonia were 
the common causes of urinary tract infection at 40.7% and 15.3% respectively with 22% 
cases on extended beta lactam resistance. 
Conclusions: There was no statistically significant difference on the incidence and 
anti-microbial isolates between HIV infected and HIV negative nephrology patients 
with urinary tract infection. Escherichia coli and Klebsiella pneumoniae were the most 
commonly cultured organisms in both groups. There is microbial resistance to 
commonly used antibiotics. 
 Recommendations: Constant assessment of anti-microbial sensitivity of urinary 





Urinary tract infection (UTI) is an infection of the urinary system which includes 
urethra, bladder (cystitis), ureter and kidneys (pyelonephritis). It can be symptomatic or 
asymptomatic bacteriuria (ABU).  
The risk of urinary tract infection is higher in elderly, pregnant women, 
immunocompromised, diabetic, post renal transplant, post spinal injuries, patients 
admitted in the past three months, patients with urinary catheters and patients with 
urologic abnormalities. Nephrology patients have most of these risk factors. 
 
Nephrology unit at Inkosi Albert Luthuli Central hospital (IALCH) caters for all 
nephrology patients in the public sector in KwaZulu Natal province (KZN). This means 
there is always a list of patients waiting for bed availability in order to be transferred 
across to the unit. Most of these patients have been inpatients at other hospitals before 
transfer to the unit and some have had urinary catheters inserted at the referring 
hospitals, which increases their risk of urinary tract infections. All patients that are seen 
in the unit have urine dipsticks and urine microscopy culture and sensitivity done as part 
of the nephrology work up. UTI can worsen the renal function leading to early 
requirement for renal replacement therapy (RRT) thereby increasing mortality and 
morbidity, delays invasive procedures and increases hospital stay. This leads to longer 
waiting period for beds.  It is therefore of paramount importance that the unit is aware 
of the incidence and antimicrobial susceptibility of the UTIs for early treatment and 
prevention of complications associated with UTIs. 
 
KZN has the highest burden of HIV disease in the South Africa 
[1]
. HIV infected 
patients have higher risk of acquiring kidney disease (acute or chronic) due to the 
effects HIV virus on the renal system, immune mediated mechanisms, risk of infections 
and side effects of antiretroviral therapy (ART). HIV infected patients have been shown 
to have increased risk of UTI 
[2-4]
.  
Patients with diabetes mellitus, systemic lupus erythematosus (SLE) and post renal 
transplant have higher risk of acquiring both kidney disease and UTI and are mostly 






Escherichia coli (E. coli) is the most common cause of UTI in community acquired, 
hospital acquired, pregnant, HIV positive and negative, Diabetic, SLE and post renal 
transplant cohorts of  patients
[2-7, 20-21]
.  
E. coli is the predominant isolate in UTI in South Africa 
[21, 22],
  continent of Africa
 [23-28]
 
and the rest of the world
 [29-31]
. 
Enterobacteriaceae, Klebsiella, Pseudomonas aeruginosa, Enterococci, Staphylococci, 
and fungi are also significant causes 
[32]
. 
Early diagnosis and treatment of UTI is key on preventing complications but  increasing 
resistance of the micro-organism causing UTI to the commonly used antibiotics, 
emergence of extended beta lactam resistance (ESBL) and multiple drug resistance 
(MDR)
  
 strains is a major challenge 
[32-36]
. It is therefore vital for health care facilities to 
be aware of the resistant strain and microbial sensitivity in their facility in order to 
choose appropriate effective antibiotics. 
Prevention strategies include restricting insertion of urinary catheters unless absolutely 
indicated, intermittent catheterization, vaginal oestrogens for perimenopausal women 
and use of cranberry products in high risk patients
 [36-38]
. 
There is limited data on the incidence and antimicrobial susceptibility in HIV negative 
and positive nephrology patients specifically, the objective of the study was to bridge 
that gap and to be able to choose appropriate treatment early in our facility in order to 















This is a retrospective chart review of nephrology patients seen in 2014. The study 
protocol was approved by Biomedical Research Ethics Committee (BREC) reference 
number BE496/15, Department of Health reference number HRKM049/17 and IALCH 
CEO. 
 The study included all nephrology patients admitted at IALCH from January to 
December 2014 and the first 200 out of 5843 outpatients (CI 95%, margin of error 
6.9%, proportion estimate 50%) seen in nephrology clinic in 2014. Only the first 
admission was considered for patients who were admitted more than once in the same 
year. Patient’s medical chart and laboratory records were reviewed to obtain 
demographics, HIV status, underlying renal disease and urine culture.  
Patients were divided into two groups based on HIV status as documented on the chart 
or laboratory results. CD4 count and viral load was obtained from laboratory results for 
all the HIV positive patients 
UTI was based on positive urine culture results. Patients with positive urine culture had 
their charts reviewed further for symptoms, signs, dipstick, urine sensitivity and 
treatment given. All data was gathered using a data collection sheet.  
The data collected was captured and   analysed using the Statistical Package for Social 
Sciences (SPSS version 23). Percentages of basic characteristics were calculated and 
comparative percentages between groups (i. e HIV negative and HIV positive) were 
performed. Logistic regression analysis was used to identify factors associated with 
positive urine culture. All tests of significance were two-sided and a confidence interval 













Baseline characteristics of patients 
TABLE 2 demonstrates  the baseline characteristics and urine culture of HIV positive 
and negative patients included in the study; there were 59 (9%) patients with confirmed 
UTI, 46 (78%) inpatients and 13 (22%) outpatients, 43 (73%) females and 16 (27%) 
males. 46 (78%) were HIV negative  and 13 (22%) of patients were HIV positive.  
E. coli was cultured in 24 (40.7%) patients, 6 (46.1%) HIV positive and 18 (39.1%) 
HIV negative while K. Pneumonia was cultured in 9 (15.3%) of the patients, 2 (15.4%) 
HIV positive and 7 (15.2%) HIV negative.  
47 (79.7%) of the patients had no urinary symptoms recorded, 8 (13.6%) presented with 
fever, 2 (3.4%) had dysuria and 2 ( 3.4%)  had flank pain. 44 (74.6%) had no signs, 8 ( 
13.6%) had tachycardia,  6 ( 10.2%) had pyrexia, and 1 (1.7%) had suprapubic 
tenderness. 
 
The incidence of UTI was 10.1% and 6.5% among inpatients and outpatients 
respectively (see Table 3).   
Table 3 shows sample size and distribution of patients; there were 654 patients in total, 
815 were admissions of which 361 were re-admissions, one admission per patient was 
counted giving total of 454 inpatients and 200 outpatients  
The mean age was 42 (11-78). 
Out of the 654 patients, 515 (79%) were HIV negative and 139 (21%) HIV positive of 
which 127 (91%) were on ART, 11 (8%) not on ART, 1 (1%) unknown. 
 
UTI risk factors 
In a multivariate analysis the risk factors associated with UTI in nephrology patients 
were HIV infection (95% CI, 0.883 0.550-2.003; p 0.883), diabetes mellitus (95% CI, 
0.187-0.107; p 0.332), SLE (95% CI, 0.020-0.38; p 0.35) and post renal transplant ( 
95% CI, 0.040-0.089; p 0.208) see Table 4. 
11 (85%) of the HIV positive patients were on ART, 2 (15%) were not on ART, the 






Table 5 shows urinalysis findings on the patients with positive urine culture, protein was 
the predominant finding in 80% of the patients, blood was in 70.9%, leucocytes in 
32.7% and nitrites in 10.9%. 
 
TABLE 2: BASELINE CHARACTERISTICS OF PATIENTS INCLUDED IN THE 
STUDY 
 HIV positive HIV negative p value 
No of patients n = 59 n=13 (22%) n=46 (78%) 0.883 
Gender    
Females = 43 (73%) 9 (69.2%) 34 (73.9%) 1.000 
Males = 16 (27%) 4 (30.8%) 12 (26.1%) 0.749 
In/outpatients    
Inpatients = 46 (78%) 11 (84.6%) 35 (76.1%) 0.817 
Outpatients = 13 (22%) 2 (15.4%) 11 (23.9%) 0.723 
Diabetes mellitus = 11 (19%) 1 ( 7.6%) 10 (21.7%) 0.442 
SLE = 9 (15%) 0 9 (19.5%) 0.189 
Post renal transplant = 3 (5%) 0 3 (6.5%) 1.000 
Symptoms    
Asymptomatic = 47 (79.7%) 10 (76.9%) 37 (80.4%) 1.000 
Fever = 8 (13.6%) 1 (7.7%) 7 (15.2%) 1.000 
Dysuria = 2 (3.4 %) 0 2 (4.3%) 1.000 
Flank pain = 2 (3.4 %) 2 (15.4%) 0 1.000 
Signs    
No signs = 44 (74.6%) 9 (69.2) 35 (76.1%) 1.000 
Tachycardia = 10 (16.9%) 3 (23.1) 7 (15.2%) 0.687 
Pyrexia = 6 (10.2%) 1 (7.7%0 5 (10.9%) 1.000 
Suprapubic tenderness = 1 (1.7%) 1 (7.7%) 0 0.233 
Microbial isolates    
Escherichia coli = 24 (40.7%) 6 (46, 1%) 18 (39.1%) 0.779 
Klebsiella pneumonia = 9 (15.3%) 2 (15.4%) 7 (15.2%) 1.000 
Enterococcus fecalis = 5 (8.5%) 1 (7.7%) 4 (8.7%) 1.000 
Candida albicans = 4 (6.8%) 1 (7.7%) 3 (6.5%) 1.000 
Acinobacter baumanni = 4 (6.8%) 0 4 (8.7%) 0.572 
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Pseudomonas aeruginosa = 3 
(5.1%) 
1 (7.7%) 2 (4.3%) 0.543 
Streptococcus agalactiea = 2 
(3.4%) 
0 2 (4.3%) 1.000 
Enterobacter feacalis = 1 (1.7%) 1 (7.7%) 0 0.233 
Enterococcus cloacae = 1 (1.7%) 1 (7.7%) 0 0.233 
Staphylococcus aureus = 1 (1.7%) 0 1 (2.2%) 1.000 
Proteus vulgaris = 1 (1.7%) 0 1 (2.2%) 1.000 
Proteus mirabis = 1 (1.7%) 0 1 (2.2%0 1.000 
Serratia marcescens = 1 (1.7%) 0 1 (2.2%) 1.000 
 
TABLE 3: SAMPLE SIZE AND DISTRIBUTION OF PATIENTS 
 Inpatients Outpatients p value 
N=654 454 200  
UTI= 59 (9%) 46    13    0.184 
Incidence % 10.1% 6.5%  
 
TABLE 4: UTI RISK FACTORS IN NEPHROLOGY PATIENTS 









139  21% 115  24% 56   9% 17   3% 
UTI patients 
n=59 






0.332 0.034 0.208 
*p values obtained using Pearson Chi- Square test 
 
TABLE 5: DIPSTICK OF PATIENTS WITH UTI 
 Protein Blood Leucocytes Nitrites 
n= 59 44 39 18 6 
%/100 80% 70.9% 32.7% 10.9% 
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Microbial sensitivity  
Escherichia coli and Klebsiella pneumonia 
Table 6 shows sensitivity and resistance patterns of the commonly cultured organisms, 
E. coli 24 (40.7%) and K.pneumonia 9 (15.3%).  
E coli   was mostly sensitive to Nitrofurantoin in 18 (75%) and Amoxicillin/ clavulanate 
in 13 (54.2%) and resistant to Co-trimoxazole in 11 (45.8%) and Ciprofloxacin in 9 
(35.7%). 
K. pneumonia was mostly sensitive to Meropenem/ imipenem in 5 (55.6%) and  
 Amikacin in 4 (44.4%). It was resistant to Ciprofloxacillin in 7 (77.8%) and Co-
trimoxazole in 5 (55.6%). K. pneumonia also had 2 (22.2%) of cases with ESBL 
resistant organisms.  
 Sensitivity and resistance was not reported against all the antibiotics in Table 6, i.e. E. 
coli was sensitive to Ciprofloxacin in 7 patients and resistant in 9 patients. There was no 
Ciprofloxacin sensitivity done for the other 8 patient who cultured E. coli.  
 
Candida albicans 
Candida albicans was cultured in 4 (6.8%) of patients and 3 (75%) were sensitive to 
Fluconazole with 1 (25%) case of resistance. 
 





















Ciprofloxacin 7 (29.2%) 9 (37.5%) 8 (33.3%) 2 (22.2%) 7 (77.8%) - 
Amoxicillin / 
clavulanate 
13 (54.2%) 3 (12.5%) 
8 (33.3%) 
3 (33.3%) 3 (33.3%)  
2 (22.2%) 
 
Nitrofurantoin 18 (75%) - 6 (25%) - - 9 (100%) 
Meropenem/ 
Imipenem 
5 (20.8%) - 
21 (87.5%) 




- 11 (45.8%) 
 
13 (54.2%) 





Amikacin - - 24 (100%) 4 (44.4%) - 5 (55.6%) 
ESBL - 0  - 2 (22.2%)  
 
Antibiotics used 
Table 7 shows a record of antibiotics used on the 59 patients with positive urine culture, 
27 (45.8%) unknown includes patients who were managed as ABU and patients that 
were transferred back to referring hospitals before initiation of any antibiotic. 
 
TABLE 7: ANTIBIOTICS USED 
Antibiotic N=59 / %= 100 
Unknown* 27             45.8% 
Ciprofloxacillin 10             16.9% 
Amoxicillin/clavulanate 9               15.3% 
Meropenem or Imipenem 9               15.3% 
Vancomycin 2               3.4% 
Cloxacillin 1               1.7% 
Colistin 1               1.7% 
















There was no statistical difference on incidence of UTI and microbial isolates between 
HIV negative and positive nephrology patients. This is probably due to the fact that HIV 
positive nephrology patients are required to be on ART for at least six months or have a 
suppressed viral load to be accepted to the renal program as per the South African 
National guidelines. The risk of UTI in HIV infected patients is related to immune 
function determined by lymphocyte count 
[39-40] 
   and ART improve immune function. 
The HIV positive were compared to the HIV negative  but 50% of the HIV negative in 
this study also had some form of immune suppression i.e. patients with diabetes 
mellitus, SLE and post renal transplant (see TABLE 2) which could explain the lack of 
significant difference between the two groups. 
 
The incidence of UTI in patient with diabetes mellitus of 19% (Table 4) was similar to 
the 19.5%   reported in Sudan
 [5] 
  and lower than the 25.3% in Saudi Arabia
 [9]
. The 
incidence of UTI among post renal transplant was 5% (Table 4) which is lower than the 
25% and 26-76% reported in previous studies
 [20]
. This could be attributed to the small 
(3%) number of post renal transplant patients in this study.  
 
E. coli and K. pneumonia were the most commonly cultured organisms in both HIV 
negative and positive patients (see TABLE 2), this is in contrast with a study done in 
Poland in which 1/3 of HIV infected patient cultured non-typical organisms 
[41]
. This 
difference could be explained by the fact that 85% of the HIV positive patients in our 
study were on ART.  
E. coli was the most cultured organism at 40, 7% (TABLE 2) across all groups. It is the 
most common cause of UTI across all groups in literature, in Africa 
[23-28] 




E.coli and K. pneumonia resistance was mostly to Ciprofloxacin at 37.5% and 77.8%, 
Amoxicillin/clavulanate at 12.5% and 33.3% and Co-trimoxazole at 45.8% and 55.6% 
respectively. This was not different from the previous studies done in South Africa, 
Congo and Uganda
 [23, 25, 41-43]
. This is a major concern as these are widely used first line 
drugs against UTIs.  
The antibiotic of choice for empiric treatment in our unit would be Amoxicillin/ 
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clavulanate as it has better sensitivity and less resistance when compared to 
Ciprofloxacin. 
The 22% of ESBL resistant K. pneumonia cultured in nephrology patients in 2014 has 
increased to 40% reported by Lancet laboratories in KZN in 2018 which is a major 
concern and stresses the need for constant assessment of anti-microbial culture and 
sensitivity of UTI. 
 
In this study we have shown the role of ART in reducing the risk of UTI in HIV 
positive nephrology patients as evidenced by a lack of significant difference in the 
incidence of UTI between HIV negative and positive patients.  
Previous studies were prior to the ART era, more studies are needed to assess the 
impact of ART and CD4 count on the development of UTI.  
Previous studies done on UTI focused mainly on pregnant women, urology patients and 
patients with spinal conditions and preventative strategies have been focused mainly on 
those groups. This study has highlighted that nephrology patients are also susceptible to 
UTI, compared to the general population. Therefore research on the impact of 
preventative strategies used for the other high risk groups would be beneficial in 
nephrology patients as well.  
The limitations in our study were that it was a retrospective study done in a specialised 
unit with limited number of patients and all data was dependent on information 
documented in the patient’s clinical records. 
Some cultured organisms did not have drug sensitivity done on all the drugs making 
exact resistance percentage difficult to assess. Some patients were transferred back to 
referring hospitals before initiation or completion of treatment therefore the outcomes 
could not be assessed. 
Constant research on this field would be beneficial especially now with the emergence 









Urinary tract infections are the commonest infections in out and inpatient settings. HIV 
positive, diabetes mellitus, SLE and post renal transplant cohorts of patients are 
nephrology patients which are mostly susceptible to UTIs. Delays in treating UTI may 
worsen the renal function leading to early renal replacement therapy and delays invasive 
procedures thus increasing morbidity and mortality. 
E. coli is the commonest cause of UTI in both HIV negative and positive nephrology 
patients. 
There is need for constant assessment of anti-microbial sensitivity of UTI due to 
increasing microbial resistance to commonly used antibiotics by the common organism 
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